Inventor · disambiguated record
Michael A. Caligiuri
Also filed as: CALIGIURI MICHAEL · CALIGIURI MICHAEL A
10 granted patents·30 pending applications·95 citations·filing 1997–2025
87Inventor score
Files withHOPE CITY17CYTOIMMUNE THERAPEUTICS INC8OHIO STATE INNOVATION FOUNDATION7UNIV OHIO STATE RES FOUND3HEALTH RESEARCH INC2
Top patents by PatentIndex Score
40 records- 0187US7306801B2Methods of therapy for cancers characterized by overexpression of the HER2 receptor proteinHEALTH RESEARCH INC·Filed 2001·Granted Dec 11, 2007·47 cites·10 claims
- 0279US7915043B2CD34(+) cells and their methods of useUNIV OHIO STATE RES FOUND·Filed 2006·Granted Mar 29, 2011·11 cites·17 claims
- 0377US11045543B2EGFR-directed car therapy for glioblastomaCYTOIMMUNE THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·2 cites·33 claims
- 0477US10961312B2FLT3 directed car cells for immunotherapyCYTOIMMUNE THERAPEUTICS INC·Filed 2017·Granted Mar 30, 2021·1 cites·18 claims
- 0575US10973914B2Bivalent antibody directed against NKG2D and tumor associated antigensOHIO STATE INNOVATION FOUNDATION·Filed 2016·Granted Apr 13, 2021·2 cites·14 claims
- 0675US9603873B2Activation of innate immunity by miRNA for cancer and infection treatmentOHIO STATE INNOVATION FOUNDATION·Filed 2013·Granted Mar 28, 2017·3 cites·10 claims
- 0773US2025179194A1Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1CYTOIMMUNE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0870US11459378B2Passive antibody dependent cell-mediated activationOHIO STATE INNOVATION FOUNDATION·Filed 2018·Granted Oct 4, 2022·1 cites·13 claims
- 0968US2025257138A1Immune cells expressing a hypoxia-dependent chimeric antigen receptor targeted to egfrHOPE CITY·Filed 2024·Application pending·0 cites
- 1067US2025090661A1Expansion of human group 2 innate lymphoid cells and methods of use thereofHOPE CITY·Filed 2024·Application pending·0 cites
- 1167US2025360212A1Compositions and uses of psca targeted chimeric antigen receptor modified cells expressing il-15HOPE CITY·Filed 2024·Application pending·0 cites
- 1265US2024041875A1Methods of treating a coronavirus infectionHOPE CITY·Filed 2023·Application pending·0 cites
- 1364US2025017964A1Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapyHOPE CITY·Filed 2022·Application pending·0 cites
- 1460US2008159981A1Methods of therapy for cancers characterized by overexpression of the HER2 receptor proteinNOVARTIS VACCINES & DIAGNOSTIC·Filed 2007·Application pending·0 cites
- 1560US2025186520A1Oncolytic virus compositions and methods for the treatment of cancerHOPE CITY·Filed 2021·Application pending·0 cites
- 1660US2025222102A1Nk cells expressing il-15 and checkpoint inhibitors for the treatment of cancerHOPE CITY·Filed 2022·Application pending·0 cites
- 1759US6042826AMethod for inducing apoptosis of primary central nervous system B cell lymphomasHEALTH RESEARCH INC·Filed 1997·Granted Mar 28, 2000·28 cites·22 claims
- 1859US2021308261A1Egfr-directed car therapy for glioblastomaCYTOIMMUNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1959US2015366914A1Methods for Mobilizing Hematopoietic Stem CellsOHIO STATE INNOVATION FOUNDATION·Filed 2014·Application pending·0 cites
- 2059US2021301024A1Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1CYTOIMMUNE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2159US2021269534A1Flt3 directed car cells for immunotherapyCYTOIMMUNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2257US2024082398A1Methods of preparing and expanding type i innate lymphoid cells and therapeutic uses thereofHOPE CITY·Filed 2022·Application pending·0 cites
- 2357US2023405122A1Compositions and uses of psca targeted chimeric antigen receptor modified cellsHOPE CITY·Filed 2021·Application pending·0 cites
- 2457US2024299542A1Natural killer cells engineered to reduce or eliminate cbl-b and uses thereofHOPE CITY·Filed 2022·Application pending·0 cites
- 2556US2024141295A1Novel cell lines, methods of producing natural killer cells and uses thereofHOPE CITY·Filed 2021·Application pending·0 cites
- 2655US2022281982A1Bispecific antibody car cell immunotherapyCYTOIMMUNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2755US2018207202A1Methods for mobilizing hematopoietic stem cellsOHIO STATE INNOVATION FOUNDATION·Filed 2018·Application pending·0 cites
- 2855US2023303654A1Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cellsHOPE CITY·Filed 2021·Application pending·0 cites
- 2954US2023159644A1Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignanciesHOPE CITY·Filed 2021·Application pending·0 cites
- 3053US2023227549A1Oncolytic virus compositions and methods for the treatment of cancerHOPE CITY·Filed 2021·Application pending·0 cites
- 3150US10167311B2Boronic acid esters and pharmaceutical formulations thereofOHIO STATE INNOVATION FOUNDATION·Filed 2015·Granted Jan 1, 2019·0 cites·13 claims
- 3250US2022249564A1Pdl1 positive nk cell cancer treatmentHOPE CITY·Filed 2020·Application pending·0 cites
- 3349US2009004182A1Methods to Treat or Prevent Viral-Associated Lymphoproliferative DisordersUNIV OHIO STATE RES FOUND·Filed 2005·Application pending·0 cites
- 3447US2021087275A1Bispecific antibody car cell immunotherapyCYTOIMMUNE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3547US2023242887A1Oncolytic virus carrying e-cadherin and uses thereofOHIO STATE INNOVATION FOUNDATION·Filed 2018·Application pending·0 cites
- 3646US2004038373A1Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorderFiled 2002·Application pending·0 cites
- 3745US2025228895A1Compounds to inhibit ythdf2, t helper cells lacking expression of ythdf2, and methods to treat cancerHOPE CITY·Filed 2025·Application pending·0 cites
- 3844US2022380457A1Igg antibody compositions and methods of making the sameHOPE CITY·Filed 2020·Application pending·0 cites
- 3941US2007196389A1Viral gene products and methods for vaccination to prevent viral associated diseasesUNIV OHIO STATE RES FOUND·Filed 2006·Application pending·0 cites
- 4028US8530187B2Methods for transfecting natural killer cellsCALIGIURI MICHAEL A·Filed 2005·Granted Sep 10, 2013·0 cites·10 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →